Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Chiu

Showing results (71-80 of 129) with videos related to

Pageof 13
Sort By:
British Journal of Haematology|February 8, 2018
Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myelomaNiels W C J van de Donk, Tineke Casneuf, Alessandro Di Cara, et al.
Blood Advances|May 23, 2023
Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targetingMaissa Mhibik, Erika M Gaglione, David Eik, et al.
JAMA Network Open|September 29, 2021
Assessment of the Feasibility of Using Noninvasive Wearable Biometric Monitoring Sensors to Detect Influenza and the Common Cold Before Symptom OnsetEmilia Grzesiak, Brinnae Bent, Micah T McClain, et al.
The Journal of Infectious Diseases|June 27, 2022
Wearable Sensor-Based Detection of Influenza in Presymptomatic and Asymptomatic IndividualsDorota S Temple, Meghan Hegarty-Craver, Robert D Furberg, et al.
Leukemia|February 1, 2020
Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 studyNizar J Bahlis, Meletios A Dimopoulos, Darrell J White, et al.
Lancet (London, England)|September 11, 2021
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 studyMartin Hutchings, Rogier Mous, Michael Roost Clausen, et al.
Arthritis Research & Therapy|May 4, 2018
Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosusSuzanne Cole, Alice Walsh, Xuefeng Yin, et al.
Haematologica|July 13, 2019
Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimensAnna Vidal-Crespo, Alba Matas-Céspedes, Vanina Rodriguez, et al.
Vaccine|February 25, 2022
Ethics review of COVID-19 human challenge studies: A joint HRA/WHO workshopEloise Williams, Kathrine Craig, Christopher Chiu, et al.
Plos Neglected Tropical Diseases|January 9, 2026
Proceedings of the inaugural symposium on dengue human challenge studies "Challenging the norm: Accelerating dengue countermeasures through human studies"Shirin Kalimuddin, Adam T Waickman, Panisadee Avirutnan, et al.
Pageof 13

Showing results (71-80 of 129) with videos related to

Sort By:
Pageof 13
British Journal of Haematology|February 8, 2018
Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myelomaNiels W C J van de Donk, Tineke Casneuf, Alessandro Di Cara, et al.
Blood Advances|May 23, 2023
Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targetingMaissa Mhibik, Erika M Gaglione, David Eik, et al.
JAMA Network Open|September 29, 2021
Assessment of the Feasibility of Using Noninvasive Wearable Biometric Monitoring Sensors to Detect Influenza and the Common Cold Before Symptom OnsetEmilia Grzesiak, Brinnae Bent, Micah T McClain, et al.
The Journal of Infectious Diseases|June 27, 2022
Wearable Sensor-Based Detection of Influenza in Presymptomatic and Asymptomatic IndividualsDorota S Temple, Meghan Hegarty-Craver, Robert D Furberg, et al.
Leukemia|February 1, 2020
Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 studyNizar J Bahlis, Meletios A Dimopoulos, Darrell J White, et al.
Lancet (London, England)|September 11, 2021
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 studyMartin Hutchings, Rogier Mous, Michael Roost Clausen, et al.
Arthritis Research & Therapy|May 4, 2018
Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosusSuzanne Cole, Alice Walsh, Xuefeng Yin, et al.
Haematologica|July 13, 2019
Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimensAnna Vidal-Crespo, Alba Matas-Céspedes, Vanina Rodriguez, et al.
Vaccine|February 25, 2022
Ethics review of COVID-19 human challenge studies: A joint HRA/WHO workshopEloise Williams, Kathrine Craig, Christopher Chiu, et al.
Plos Neglected Tropical Diseases|January 9, 2026
Proceedings of the inaugural symposium on dengue human challenge studies "Challenging the norm: Accelerating dengue countermeasures through human studies"Shirin Kalimuddin, Adam T Waickman, Panisadee Avirutnan, et al.
Pageof 13